Monopar Therapeutics (MNPR) — SEC Filings

Latest SEC filings for Monopar Therapeutics (MNPR), explained in plain English.

Sentiment Overview: 1 bearish, 45 neutral, 1 mixed

Recent Filings (47)

• Monopar Files 10-K/A for 2025 Annual Report, Details Pending — 10-K/A · 2026-04-01T12:24:15-04:00 [mixed] Risk: medium
  Monopar Therapeutics (MNPR) filed a 10-K/A, an amendment to its annual report, on 2026-04-01, covering the fiscal period ended 2025-12-31. The provided EDGAR fi
• 10-Q Filing — 10-Q · 2025-11-13T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-11-10T00:00:00.000Z [neutral]
• Monopar Therapeutics Enters Material Definitive Agreement — 8-K · 2025-09-24T00:00:00.000Z [neutral] Risk: medium
  Monopar Therapeutics Inc. announced on September 23, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with
• Monopar Therapeutics Files 8-K — 8-K · 2025-09-15T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on September 15, 2025, reporting on its corporate activities. The filing indicates no specific material events or financi
• Monopar Therapeutics Q2 2025 10-Q Filed — 10-Q · 2025-08-12T00:00:00.000Z [neutral] Risk: medium
  Monopar Therapeutics filed its 10-Q for the period ending June 30, 2025. The company reported cash and cash equivalents of $6,127,457 as of June 30, 2025. This
• Monopar Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · 2025-06-23T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on June 23, 2025, reporting a submission of matters to a vote of security holders on June 17, 2025. The company, incorpor
• Monopar Therapeutics Files Proxy Materials — DEFA14A · 2025-05-23T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed a Definitive Additional Materials proxy statement on May 23, 2025. This filing relates to the company's proxy materials and does
• Monopar Therapeutics Files 8-K — 8-K · 2025-05-13T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on May 13, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhi
• Monopar Therapeutics Files 8-K — 8-K · 2025-05-07T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on May 7, 2025, reporting an event that occurred on the same date. The filing is a current report pursuant to Section 13
• Monopar Therapeutics Files 2025 Proxy Statement — DEF 14A · 2025-04-30T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed its definitive proxy statement on April 30, 2025, for its annual meeting of stockholders scheduled for June 17, 2025. The filing
• Monopar Therapeutics Files 2024 10-K — 10-K · 2025-03-31T00:00:00.000Z [neutral] Risk: medium
  Monopar Therapeutics filed its 2024 10-K, reporting total assets of $14,338,403 as of December 31, 2024. The company had cash and cash equivalents of $6,102,560
• Monopar Therapeutics Reports Officer/Director Changes & Compensatory Info — 8-K · 2025-03-03T00:00:00.000Z [neutral] Risk: medium
  Monopar Therapeutics Inc. filed an 8-K on March 3, 2025, reporting events as of February 27, 2025. The filing primarily concerns the departure of directors or c
• Monopar Therapeutics Relocates Principal Executive Offices — 8-K · 2025-02-24T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. announced on February 19, 2025, a change in its principal executive offices to 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091. This
• Monopar Therapeutics Files 8-K: Material Agreement & Equity Sales — 8-K · 2024-12-23T00:00:00.000Z [neutral] Risk: medium
  Monopar Therapeutics Inc. entered into a material definitive agreement on December 20, 2024. The company also reported on unregistered sales of equity securitie
• Tactic Pharma LLC Amends Monopar Therapeutics Stake — SC 13D/A · 2024-12-17T00:00:00.000Z [neutral] Risk: medium
  Tactic Pharma LLC, through an amendment filed on December 17, 2024, has updated its Schedule 13D regarding Monopar Therapeutics Inc. The filing indicates a chan
• Monopar Therapeutics Files 8-K — 8-K · 2024-12-06T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on December 6, 2024, reporting on events that occurred on the same date. The filing primarily concerns financial statemen
• Monopar Therapeutics Files 8-K on Financials — 8-K · 2024-11-08T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on November 8, 2024, to report on its results of operations and financial condition. The filing includes financial statem
• SC 13G Filing — SC 13G · 2024-11-06T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-10-31T00:00:00.000Z [neutral]
• Monopar Therapeutics Files 8-K: Material Agreement — 8-K · 2024-10-30T00:00:00.000Z [neutral] Risk: medium
  Monopar Therapeutics Inc. announced on October 28, 2024, that it entered into a material definitive agreement. The company also disclosed information related to
• SC 13G Filing — SC 13G · 2024-10-28T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-10-24T00:00:00.000Z [neutral]
• Monopar Therapeutics Files 8-K: Acquisition, Debt, and Equity Sales — 8-K · 2024-10-24T00:00:00.000Z [neutral] Risk: medium
  On October 23, 2024, Monopar Therapeutics Inc. entered into a material definitive agreement related to the completion of an acquisition. The company also disclo
• Monopar Therapeutics Files 8-K — 8-K · 2024-10-22T00:00:00.000Z [neutral] Risk: low
  On October 22, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 1000 Skokie Bl
• Monopar Therapeutics Files 8-K — 8-K · 2024-10-15T00:00:00.000Z [neutral] Risk: low
  On October 15, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits
• Monopar Therapeutics Files 8-K — 8-K · 2024-10-07T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on October 7, 2024, reporting on events that occurred on the same date. The filing is primarily a cover page and does not
• Monopar Therapeutics Files 8-K — 8-K · 2024-09-12T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on September 12, 2024, reporting an event under Regulation FD Disclosure and Financial Statements and Exhibits. The filin
• Monopar Therapeutics Files 8-K Report — 8-K · 2024-08-27T00:00:00.000Z [neutral] Risk: low
  On August 27, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No
• Monopar Therapeutics Files 8-K — 8-K · 2024-08-21T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on August 21, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
• Monopar Therapeutics Files 8-K — 8-K · 2024-08-14T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on August 14, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
• Monopar Therapeutics Q2 2024 10-Q Filed — 10-Q · 2024-08-09T00:00:00.000Z [neutral] Risk: medium
  Monopar Therapeutics filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $17,601,827 as of June 30, 2024. The
• Monopar Therapeutics Sets August 5th Annual Meeting — DEF 14A · 2024-07-22T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed a definitive proxy statement (DEF 14A) for its annual meeting of stockholders scheduled for August 5, 2024. The filing indicates
• Monopar Therapeutics Files 8-K — 8-K · 2024-07-09T00:00:00.000Z [neutral] Risk: medium
  Monopar Therapeutics Inc. filed an 8-K on July 9, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
• Monopar Therapeutics Files 8-K — 8-K · 2024-06-11T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on June 11, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not cont
• Monopar Therapeutics Files 8-K — 8-K · 2024-06-10T00:00:00.000Z [neutral] Risk: low
  On June 10, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No s
• Monopar Therapeutics Appoints New Chief Medical Officer — 8-K · 2024-05-24T00:00:00.000Z [neutral] Risk: medium
  Monopar Therapeutics Inc. announced on May 23, 2024, the appointment of Dr. Andrew "Andy" Mueller as Chief Medical Officer. Dr. Mueller, who previously served a
• Monopar Therapeutics Q1 2024 10-Q: Cash & Investments Detailed — 10-Q · 2024-05-09T00:00:00.000Z [neutral] Risk: medium
  Monopar Therapeutics filed its 10-Q for the period ending March 31, 2024. The company reported cash and cash equivalents of $17,484,175 and investments of $14,9
• Monopar Therapeutics Files 8-K Report — 8-K · 2024-04-16T00:00:00.000Z [neutral] Risk: low
  On April 16, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates
• Monopar Therapeutics Files 8-K — 8-K · 2024-04-10T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on April 10, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contai
• Monopar Therapeutics Files 8-K — 8-K · 2024-03-28T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on March 28, 2024, to report on its results of operations and financial condition. The filing does not contain specific f
• Monopar Therapeutics Files 8-K for Regulation FD Disclosure — 8-K · 2024-03-07T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on March 7, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or materia
• Monopar Therapeutics Files 8-K: Financials & Exhibits — 8-K · 2024-03-05T00:00:00.000Z [neutral] Risk: low
  On March 5, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates o
• Monopar Therapeutics Faces Potential Delisting Notice — 8-K · 2024-02-28T00:00:00.000Z [bearish] Risk: high
  Monopar Therapeutics Inc. filed an 8-K on February 28, 2024, reporting that on February 27, 2024, it received a notice of delisting or failure to satisfy a cont
• Monopar Therapeutics Files 8-K Current Report — 8-K · 2024-02-27T00:00:00.000Z [neutral] Risk: medium
  Monopar Therapeutics Inc. filed an 8-K Current Report on February 27, 2024, disclosing Regulation FD information and Financial Statements and Exhibits. The spec
• Monopar Therapeutics Files 8-K for Regulation FD Disclosure — 8-K · 2024-02-22T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on February 22, 2024, indicating a Regulation FD Disclosure and Financial Statements and Exhibits. The filing, under SEC
• Monopar Therapeutics Files 8-K for Regulation FD Disclosure — 8-K · 2024-02-20T00:00:00.000Z [neutral] Risk: low
  Monopar Therapeutics Inc. filed an 8-K on February 20, 2024, under accession number 0001437749-24-004724. The filing indicates a Regulation FD Disclosure and in